In patients who had progressed on one prior ARPI, FG3246 plus enzalutamide yielded a median radiographic progression-free survival (rPFS) of 10.1 months and PSA50 response of 40%. Phase I Monotherapy ...
Companies are using A.I. as a reason for layoffs, but the truth may be more complex. By Kevin RooseCasey NewtonRachel CohnWhitney JonesVjeran PavicKatie McMurranDan PowellRowan Niemisto and Diane Wong ...
Free with your TV subscription. More Information and FAQ NOW: Senators Hear Testimony on Birthright Citizenship Ahead of Supreme Court Case NOW: The War on Illahee NOW: Resistance Art in Nazi-Occupied ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果